Skip to Main Content

Paper Details

Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer.
Lung Cancer
5
2023
Author NameAffiliation
Chul AhnHarold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, USA Peter O'Donnell Jr. School of Public Health
  • 1 - 1

Datasets

Release 1.2